top of page
ORPHEUS
A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF INCMGA00012 IN ADVANCED PENILE SQUAMOUS CELL CARCINOMA – ORPHEUS
CLINICAL TRIAL DETAILS
ORPHEUS IS AN INTERNATIONAL, MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II CLINICAL TRIAL IN MEN WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PENILE SQUAMOUS CELL CARCINOMA (PSCC). THE PRIMARY GOAL IS TO ASSESS THE EFFICACY –AS DETERMINED BY THE OBJECTIVE RESPONSE RATE (ORR)– OF INCMGA00012 IN THE STUDY POPULATION. IN ADDITION, THIS STUDY WILL ALSO EVALUATE THE SAFETY AND TOLERABILITY OF INCMGA00012 IN THESE PATIENTS.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
PENILE
13
18
II
Spain, Italy
Closing
TRIAL OVERVIEW
PRESS RELEASE
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
Promising Advancements in Oncology Research Unveiled at ASCO Annual Meeting
Spotlight - ORPHEUS Penile carcinoma trial
MEDSIR’s Experience at ASCO GU 2022: Update on our 2 GU trials
We’re presenting at ASCO GU 2022!
ORPHEUS: A study of the efficacy of immunotherapy for advanced cases of penile cancer
ORPHEUS Study: Evaluation of Retifanlimab In Penile Cancer
TRIAL SITES
ICO L'Hospitalet, Catalan Institute of Oncology (Spain)
Hospital Insular de Gran Canaria (Spain)
Hospital Virgen de la Arrixaca (Spain)
Hospital Virgen del Rocío (Spain)
Hospital Miguel Servet (Spain)
Instituto Valenciano de Oncología (Spain)
Hospital de la Santa Creu i Sant Pau (Spain)
Hospital Universitario Doce de Octubre (Spain)
Hospital Clínico San Carlos (Spain)
Hospital Universitari Son Espases (Spain)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (Italy)
AUSL Reggio Emilia (Italy)
Ospedale San Raffaele (Italy)
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page